Abstracts tagged "positron emission tomography (PET) and takayasu arteritis"

Abstract Number: 2196 • 2018 ACR/ARHP Annual Meeting
Kinetics of Tissue-Specific Distribution of 18f-Fluorodeoxyglucose in Positron Emission Tomography in Large Vessel Vasculitis
Joel S. Rosenblum¹, Kaitlin Quinn², Mark A. Ahlman³ and Peter C. Grayson⁴, ¹NIAMS, National Institute of Arthritis, Musculoskeletal and Skin Disease (NIAMS), Bethesda, MD, ²Systemic Autoimmunity Branch, NIAMS, Bethesda, MD, ³Radiology and Imaging Sciences, National Institutes of Health, Bethesda, MD, ⁴National Institute of Arthritis, Musculoskeletal and Skin Disease, National Institutes of Health, Bethesda, MD
Background/Purpose: 18F-fluorodeoxyglucose (FDG) PET may be used to quantify vascular inflammation in large-vessel vasculitis (LVV). Quantitative analysis of arterial FDG uptake has not been standardized. Delayed…
Abstract Number: 801 • 2017 ACR/ARHP Annual Meeting
PET-CT Findings and Clinical Outcomes in Takayasu Arteritis – Does 18F-Fluorodeoxyglucose Uptake in Arteries Predict Relapses?
Anna Larissa Faria Janes¹, Míriam Fang Castro¹, Bruna Savioli¹, Anne Elisabeth Diniz Arraes¹, Emilia Sato² and Alexandre W.S. Souza³, ¹Internal Medicine - Rheumatology Division, Universidade Federal de São Paulo - Escola Paulista de Medicina, São Paulo, Brazil, ²Rheumatology Division, Universidade Federal de Sao Paulo, Sao Paulo, Brazil, ³Rheumatology Div/Dept of Med, Escola Paulista de Medicina - Universidade Federal de São Paulo, Sao Paulo, Brazil
Background/Purpose: PET-CT scan with 18F-Fluorodeoxyglucose (18F-FDG) has been frequently used as a tool to assess disease activity in Takayasu arteritis (TA) and increased 18F-FDG uptake…
Abstract Number: 862 • 2016 ACR/ARHP Annual Meeting
Utility of 18f FDG Positron Emission Tomography (PET) As a Diagnostic Test and Marker of Disease Activity in Large Vessel Vasculitis
Sara Alehashemi¹, Mark Ahlman², Ali Cahid Civelek², Elaine Novakovich³, Ashkan Malayeri², Peter A. Merkel⁴, Thomas Cupps⁵, David Bluemke² and Peter C. Grayson³, ¹Rheumatology, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²Radiology and Imaging Sciences, National Institutes of Health, Bethesda, MD, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁴Division of Rheumatology, Univ of Pennsylvania; Perelman School of Med, Philadelphia, PA, ⁵Rheumatology, Georgetown University, Bethesda, MD
Background/Purpose: FDG-PET may have a role in diagnosing and monitoring disease activity in large vessel vasculitis (LVV). Studies that assess the diagnostic accuracy of PET…
Abstract Number: 892 • 2016 ACR/ARHP Annual Meeting
FDG-PET CT Evaluation By Visual Grading Is Not Sufficiently Discriminative to Assess Disease Activity in Takayasu’s Arteritis Patients with ‘Persistent’ Disease
Ali Ugur Unal¹, Fuat Dede², Tanju Yusuf Erdil², Tunc Ones², Fatma Alibaz-Oner³ and Haner Direskeneli⁴, ¹Marmara University, School of Medicine, Rheumatology, Istanbul, Turkey, ²Department of Nuclear Medicine, Marmara University Faculty of Medicine, Istanbul, Turkey, ³Department of Rheumatology, Marmara University Faculty of Medicine, Istanbul, Turkey, ⁴Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey
Background/Purpose: Takayasu arteritis (TAK) is a large-vessel vasculitis in which assessment of disease activity is challenging. Recent studies support that 18F-fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].